Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis (FMTUC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02390726|
Recruitment Status : Active, not recruiting
First Posted : March 17, 2015
Last Update Posted : July 9, 2018
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) for treating patients with mild to moderate Ulcerative Colitis (UC). Even with the expanding choices of medication for UC, physicians and patients are still in search of highly effective and safe medications with minimal side effects. FMT has been approved for the treatment of a bacterial infection called Clostridium difficile. In this setting, FMT has been proven to be an effective and safe alternative therapy with zero reported serious adverse events from patients that have had this treatment.
The providers that are conducting this study hypothesize that delivering microbes from a healthy human gut can help treat the damages caused by UC. This is done by "transplanting" fecal material, which contains a highly complex and dense community of healthy microbes, including bacteria, fungi and viruses. This collection of microbes is referred to as a microbiome. Preliminary studies suggest that alteration of the microbiome can help treat UC.
|Condition or disease||Intervention/treatment||Phase|
|Ulcerative Colitis, Active Moderate||Biological: Fecal Microbiota Transplant Biological: Placebo||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis|
|Study Start Date :||December 2015|
|Actual Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||September 2018|
Sham Comparator: Control
Sham FMT and Sham Microbial Maintenance plus standard therapy
FMT and microbial maintenance plus standard therapy
Biological: Fecal Microbiota Transplant
- Asses Endoscopic Stages of the Colon Pre/Post FMT [ Time Frame: 2 years ]Assess endoscopic stage of the inflamed colon (endoscopic Mayo score) and assess the histologic stage of the biopsied colon (quiescent/mild/moderate/severe) pre and post FMT.
- Asses Biologic Inflammatory Markers [ Time Frame: 2 years ]Assess biologic inflammatory markers (ESR, CRP, fecal calprotectin, and fecal lactoferrin) pre and post FMT.
- Review and Track Patient reported Outcomes via Validated Questionnaires [ Time Frame: 2 Years ]Assess patient-report outcomes (symptomatology and quality of life) calculated via validated questionnaires (symptomatic Mayo Score and SF36)
- Change in metagenomic sequencing in Stool samples after FMT treatment [ Time Frame: After 6, 12, and 18 Weeks ]Trace the effect FMT therapy has on microbiome diversity and to track whether this effect is sustained during and after therapy via metagenomic sequencing of stool samples at time 0, and weeks 6, 12, and 18.
- Asses changes in T-cell measures and serotonin signaling in mucosal biopsy samples and peripheral blood samples [ Time Frame: 2 years ]Explore potential therapeutic mechanisms of FMT therapy. Changes in the host immune response before and after treatment will be assessed via measurement of both mucosal and peripheral T-cells populations (Th1, Th2, Th17) using mucosal biopsies and blood samples respectively.Changes in mucosal serotonin signaling will be measured using mucosal biopsies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02390726
|United States, Vermont|
|The University of Vermont Medical Center|
|Burlington, Vermont, United States, 05401|
|Principal Investigator:||Peter L Moses, MD||The University of Vermont Medical Center|